On Thursday, Moderna Inc (NASDAQ:MRNA) stock plunged as the company lowered its 2024 sales guidance due to weaker demand for its COVID-19 vaccines.
Moderna now projects 2024 net sales of between $3 billion and $3.5 billion from its respiratory franchise versus previous guidance of about $4 billion, citing low EU sales in 2024, potential revenue deferrals for certain international sales into 2025, and an increasingly competitive environment for respiratory vaccines in the U.S.
Moderna reported second-quarter revenue of $241 million, compared with $344 million a year earlier, beating the consensus of $132.18 million.
Net loss was $1.28 billion, or $3.33 a share, versus a loss of $1.38 billion, or $3.62 a share, a year earlier, surpassing the consensus of $(3.36).
Sales for Spikevax, the company’s Covid-19 vaccine, fell 37% year-over-year to $184 million.
“During the second quarter, we marked the approval of our second mRNA product and significantly lowered our operating costs. We remain focused on execution for the 2024-25 COVID season and the launch of our RSV vaccine in the U.S.,” said Stéphane Bancel, CEO.
Guidance: For the second half of the year, Moderna expects a sales split of 40-50% in the third quarter, with the balance in the fourth quarter of 2024, subject to the timing of regulatory approvals.
Price Action: MRNA stock is down 17.10% at $98.84 at the last check on Thursday.
Read Next:
Photo via Wikimedia Commons
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
